BREO Ellipta (fluticasone
furoate/vilanterol trifenatate),
approved by the Therapeutic
Goods Administration for
asthma and chronic obstructive
pulmonary disease (COPD), is the
first combination of an inhaled
corticosteroid and a long acting
beta agonist vilanterol that is
administered once daily.
The availability of a once-daily
corticosteroid with a once-daily
long acting beta-agonist in the
same inhaler was an exciting
development for patients and
doctors, respiratory specialist
Professor Grant Waterer said.The above article was sent to subscribers in Pharmacy Daily's issue from 12 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 May 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.